Abbonarsi

A novel self-propelled disposable colonoscope is effective for colonoscopy in humans (with video) - 31/05/16

Doi : 10.1016/j.gie.2015.08.083 
Nathan Gluck, MD, PhD 1, 2, , Alaa Melhem, MD 1, 2, Zamir Halpern, MD 1, 2, Klaus Mergener, MD 3, Erwin Santo, MD 1, 2
1 Tel Aviv Medical Center, Tel Aviv, Israel 
2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 
3 Digestive Health Services, Tacoma, Washington, USA 

Reprint requests: Nathan Gluck, MD, PhD, Tel Aviv Medical Center, Research Center for Digestive Disorders and Liver Diseases, 6 Weizmann St., Tel Aviv 64239, Israel.Tel Aviv Medical Center, Research Center for Digestive Disorders and Liver Diseases6 Weizmann St.Tel Aviv 64239Israel

Abstract

Background and Aims

The self-propelled disposable colonoscope (SPDC) with a 360° view is designed to enhance visualization, minimize risks of perforation and infection transmission, and shorten operator training time associated with conventional colonoscopy (CC). We evaluated SPDC efficacy for cecal intubation and safety.

Methods

Prospective patients presenting for colorectal cancer screening underwent SPDC immediately followed by CC. Initial patients necessary for SPDC operators to achieve proficiency comprised the training cohort. Subsequent enrolled patients comprised the study cohort. SPDC colonoscopy was performed up to the cecum, where anatomic landmarks were photographed and mucosal suction marks were placed. During SPDC withdrawal, polyps were recorded and similarly marked. On the second pass (by using CC), any potential mucosal damage and suction marks from the SPDC as well as polyps were recorded. Main endpoints included SPDC cecal intubation rates, confirmed by anatomic landmarks and residual marks seen on subsequent CC, and frequency and severity of adverse events and mucosal damage with SPDC. The secondary endpoint was subjective procedure proficiency, evaluated by the operator based on the training cohort. The tertiary endpoint was documenting pathologies visualized with SPDC.

Results

Fifty-six of 58 enrolled subjects completed the study. Proficiency with SPDC was attained after 8 to 10 procedures. Cecal intubation was successful in 98.2% (55/56 subjects; 95% confidence interval [CI], 90.4%-99.9%), including 100% (95% CI, 90.7%-100%) of the study cohort and 94.4% (95% CI, 72.7%-99.9%) of the training cohort. No mucosal damage or adverse events were reported. SPDC detected 87.5% of polyps seen in tandem CC, including all polyps larger than 5 mm.

Conclusions

SPDC was highly successful, simple to use, and safe in achieving complete colonoscopy (cecal intubation). (Clinical trial registration number: 0692-12-TLV.)

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : CC, CI, CIR, CRC, SPDC


Mappa


 DISCLOSURE: Dr Halpern is a consultant for GI View Ltd. All other authors disclosed no financial relationships relevant to this article.


© 2016  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 83 - N° 5

P. 998 - maggio 2016 Ritorno al numero
Articolo precedente Articolo precedente
  • Randomized, double-blind trial of CO2 versus air insufflation in children undergoing colonoscopy
  • Matjaž Homan, Dora Mahkovic, Rok Orel, Petar Mamula
| Articolo seguente Articolo seguente
  • Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy
  • Parakkal Deepak, Gregory J. Hanson, Joel G. Fletcher, William J. Tremaine, Darrell S. Pardi, John B. Kisiel, Kenneth W. Schroeder, Louis M. Wong Kee Song, William S. Harmsen, Edward V. Loftus, David H. Bruining

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.